Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of AUTX-703 in Participants With Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

NCT06846606 is registered in ClinicalTrials.gov with Auron Therapeutics, Inc. as lead sponsor.

NCT NCT06846606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06846606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of AUTX-703 in Participants With Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Lead sponsor
Auron Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
May 1, 2025
Completion date
June 30, 2028
Enrollment
69 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

refractory acute myeloid leukemia (aml), refractory myelodysplastic syndromes, relapsed acute myeloid leukemia (aml), relapsed myelodysplastic syndromes, relapsed/refractory (r/r) acute myeloid leukemia (aml), relapsed/refractory aml